Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Dora Koller"'
Publikováno v:
Human Genetics.
Autor:
Salvatore D’Antona, Gita A. Pathak, Dora Koller, Danilo Porro, Claudia Cava, Renato Polimanti
Publikováno v:
Human Genetics.
Leveraging genome-wide association statistics generated from a large study of amyotrophic lateral sclerosis (ALS; 29,612 cases and 122,656 controls) and UK Biobank (UKB; 4,024 phenotypes, up to 361,194 participants), we conducted a phenome-wide analy
Autor:
Frank R. Wendt, Gita A. Pathak, Joseph D. Deak, Flavio De Angelis, Dora Koller, Brenda Cabrera-Mendoza, Dannielle S. Lebovitch, Daniel F. Levey, Murray B. Stein, Henry R. Kranzler, Karestan C. Koenen, Joel Gelernter, Laura M. Huckins, Renato Polimanti
Publikováno v:
Molecular Psychiatry. 27:2206-2215
Autor:
Diana Grajales, Patricia Vázquez, Mónica Ruíz-Rosario, Eva Tudurí, Mercedes Mirasierra, Vítor Ferreira, Ana B. Hitos, Dora Koller, Pablo Zubiaur, Juan C. Cigudosa, Francisco Abad-Santos, Mario Vallejo, Iván Quesada, Boaz Tirosh, Gil Leibowitz, Ángela M. Valverde
Publikováno v:
Diabetologia
[Aims/hypothesis]: Second-generation antipsychotic (SGA) drugs have been associated with the development of type 2 diabetes and the metabolic syndrome in patients with schizophrenia. In this study, we aimed to investigate the effects of two different
Autor:
Paula Soria-Chacartegui, Francisco Abad-Santos, Dora Koller, Dolores Ochoa, Marcos Navares-Gómez, Manuel Román, Gina Mejía, Susana Almenara, Miriam Saiz-Rodríguez, Pablo Zubiaur
Publikováno v:
Advances in Therapy. 37:3537-3550
Dabigatran is a direct oral anticoagulant (DOAC) used for the treatment of several thrombotic conditions. To date, very few pharmacogenetic studies on dabigatran were published. We aimed to investigate the influence of 59 polymorphisms in 15 genes (i
Autor:
Dora Koller, Manuel Román, M. Aguilar, Francisco Abad-Santos, Pablo Zubiaur, Miriam Saiz-Rodríguez, Itziar de Pablo, Mª Ángeles Gálvez, Dolores Ochoa
Publikováno v:
Advances in Therapy
Exogenous progesterone is prescribed for a variety of conditions with endogenous progesterone deficiency, e.g. menstrual alterations, primary or secondary infertility or premenopause. To the best of our knowledge, no pharmacogenetic studies have been